- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00906035
The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)
August 2, 2017 updated by: University of Pennsylvania
This research study will evaluate the effects of aspirin and dipyridamole alone and in combination on the blood flow in the vessels of the legs.
We will examine how these medications are able to inhibit the clotting of platelets in the vessels of patients with PAD, and thereby affect the blood flow in the legs.
Platelets are cells in the blood that have the ability to adhere to each other to form clots.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Dipyridamole has been reformulated to guarantee systemic bioavailability and steady state levels compatible with inhibition of platelet aggregation ex vivo (1).
This newly formulated dipyridamole has been shown to roughly equal in efficacy to low dose aspirin in the secondary prevention of stroke and the drug combination seems roughly additive (2).
The present study is designed to explore two potential mechanisms which have been linked to dipyridamole action on the vessel wall; modulation of vascular eicosanoid generation and prevention of oxidant stress (3).
We shall address the hypothesis that dipyridamole affects these systems in patients with PAD.
These individuals have disordered platelet-vascular interactions, as reflected by increased generation of thromboxane, an index of platelet activation and of prostacyclin, probably a homeostatic response to traumatic and chemical stimulation of the endothelium (4,5).
Furthermore, we shall assess the functional consequences of dipyridamole action, alone and in combination with aspirin compared with aspirin alone on local measurements of flow and oxygenation, including exercise tolerance, Doppler Ultrasound and Near Infrared Spectroscopy (NIRS).
Lipid peroxidation will be quantified based on mass spectrometric analysis of the major urinary isoprostane, 8,12-iso-iPF2a-VI (6,7).
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Presbyterian Hospital, 51 N. 39th St.
-
Philadelphia, Pennsylvania, United States, 19104
- Translational Research Ctr.,3400 Civic Center Blvd, Building 421, 10th floor, Room 421
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 79 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age between 18 - 79
- Women of child bearing potential using a medically acceptable method of birth control (oral/transdermal/vaginal hormonal contraception, depo-provera injection, IUD, condom with spermicide, progestin implant, tubal ligation, oophorectomy, TAH) or abstinence.
- Capacity for giving written consent
Diagnosis of PAD by:
- previous angiogram (>0.5 stenosis of a peripheral artery)
- ankle-brachial index (ABI) of systolic pressure <0.80
- previous peripheral revascularization
- Smokers who smoke < 10 cigarettes / day
Exclusion Criteria:
- Female subjects who are pregnant or nursing a child.
- Prior bleeding event related to drug therapy
- History of gastrointestinal ulceration
- History of known dipyridamole and/or aspirin allergy or intolerance
- History of coagulation, bleeding or blood disorders.
- Recent history of myocardial infarction or stroke in the previous 6 months
- Resting blood pressure of <110mmHg systolic or <60mmHg diastolic or of >165mmHg systolic or >95mmHg diastolic
- Patients with active infection as documented by abnormal laboratory tests at screen
- Concomitant serious illness, such as cancer, as per the principal investigator's discretion
- Current use of steroids for a chronic disease process
- Presence of ischemic leg ulcers
- History of contact allergies to the metal leads of the NIRS
- History of drug or alcohol abuse within the last 6 months.
- Subject who has received an experimental drug and/or used an experimental device within 30 days of screening.
- Subject who has donated ≥ one pint of blood within 8 weeks prior to screen.
- Use of aspirin for 2 weeks prior to the study
- Use of any other NSAID or COX-inhibitor for one week prior to the start of the study
- Use of any antioxidant vitamin for 2 weeks prior to the start of the study
- Use of plavix, pletal or trental for one week prior to the start of the study
- Use of acetaminophen for one week prior to each study visit
- Use of alcohol, caffeine or high fat foods for 24 hours prior to each study visit
- Has smoked any cigarettes for 24 hours prior to each study visit
- Platelet aggregation blood test less than 60 percent at Visit 1
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Dipyridamole 200mg and Aspirin 25mg bid
All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180.
All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast.
After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy.
(NIRS) of the legs.
|
All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
Other Names:
|
Active Comparator: Dipyridamole 200 mg bid
All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180.
All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast.
After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy.
(NIRS) of the legs.
|
All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
Other Names:
|
Active Comparator: Aspirin 25 mg bid
All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180.
All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast.
After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy (NIRS) of the legs.
|
All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Present Study is Designed to Explore Two Potential Mechanisms Which Have Been Linked to Dipyridamole Action on the Vessel Wall; Modulation of Vascular Eicosanoid Generation and Prevention of Oxidant Stress.
Time Frame: Predose and dosing days 30, 90 and 180
|
No analysis could be performed due to the insufficent number of participants enrolled.
Data were not collected due to study termination related to the difficulty finding participants that matched the inclusion/exclusion criteria.
|
Predose and dosing days 30, 90 and 180
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the Functional Consequences of Dipyridamole Action, Alone and in Combination With Aspirin Compared With Aspirin Alone on Local Measurements of Flow and Oxygenation. Blood Flow Reporting to Added Table.
Time Frame: Predose and dosing days 30, 90 and 180.
|
Done by doppler ultrasound.
Data could not be analyzed due to insufficient number of participants enrolled.
Data were not collected due to study termination related to the difficulty finding participants that matched the inclusion/exclusion criteria.
|
Predose and dosing days 30, 90 and 180.
|
Assess the Functional Consequences of Dipyridamole Action, Alone and in Combination With Aspirin Compared With Aspirin Alone on Local Measurements of Flow and Oxygenation. Reporting Blood Oxygenation.
Time Frame: Predose and dosing days 30, 90 and 180.
|
Reporting blood oxygenation.
Data could not be analyzed due to insufficient number of participants enrolled.
Difficulty finding participants who fit into the inclusion/exclusion criteria.
|
Predose and dosing days 30, 90 and 180.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Garret A FitzGerald, MD, University of Pennsylvania
- Principal Investigator: Emile R Mohler, MD, University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2002
Primary Completion (Actual)
March 1, 2010
Study Completion (Actual)
April 1, 2010
Study Registration Dates
First Submitted
May 20, 2009
First Submitted That Met QC Criteria
May 20, 2009
First Posted (Estimate)
May 21, 2009
Study Record Updates
Last Update Posted (Actual)
September 5, 2017
Last Update Submitted That Met QC Criteria
August 2, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Phosphodiesterase Inhibitors
- Aspirin
- Dipyridamole
Other Study ID Numbers
- 706469
- 0821
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Dipyridamole 200mg and Aspirin 25mg bid:
-
Boehringer IngelheimCompletedCerebrovascular AccidentGermany
-
Oklahoma Medical Research FoundationTerminatedSystemic Lupus ErythematosusUnited States
-
Rutgers, The State University of New JerseyBoehringer IngelheimCompleted
-
National Institute of Diabetes and Digestive and...Boston University; Washington University School of Medicine; University of Alabama... and other collaboratorsCompleted
-
Euthymics BioScience, Inc.CompletedMajor Depressive DisorderUnited States
-
Shanghai Runshi Pharmaceutical Technology Co., LtdNot yet recruiting
-
Boehringer IngelheimCompletedCoronary ArteriosclerosisIreland
-
UMC UtrechtCompletedArteriosclerosis | Brain Ischemia | Transient Ischemic AttackNetherlands
-
University of Roma La SapienzaCivic Hospital, ItalyCompletedStroke | Cardiovascular Disease | Atherosclerosis | Carotid StenosisItaly